Immunic AG
Developing oral therapies for autoimmune diseases like multiple sclerosis and celiac disease.
IMUX | NDAQ
Overview
Corporate Details
- ISIN(s):
- US4525EP1011
- LEI:
- 549300R5T12FW5MEQB20
- Country:
- United States of America
- Address:
- C/O The Corporation Trust Company, 19801 Wilmington
- Website:
- https://imux.com/
- Sector:
- Mining and quarrying
- Industry:
- Mining of non-ferrous metal ores
Description
Immunic, Inc. is a clinical-stage biotechnology company developing a pipeline of selective, orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. The company's development programs focus on creating convenient treatment options with high efficacy and favorable safety and tolerability profiles to address significant unmet patient needs. Its primary therapeutic areas of focus include multiple sclerosis and celiac disease.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-10-29 11:30 |
Regulatory News Service
Immunic to Participate in Industry and Investor Conferences in November
|
English | 9.7 KB | ||
| 2025-10-01 12:30 |
Regulatory News Service
Immunic to Participate in Scientific and Investor Conferences in October
|
English | 14.9 KB | ||
| 2025-09-25 12:30 |
Regulatory News Service
Immunic Presented Key Vidofludimus Calcium Data at the 41st Congress of ECTRIMS…
|
English | 23.6 KB | ||
| 2025-09-09 12:30 |
Regulatory News Service
Immunic Receives Notice of Allowance for United States Patent Protecting Vidofl…
|
English | 13.9 KB | ||
| 2025-09-04 12:30 |
Regulatory News Service
Immunic to Participate in Investor and Scientific Conferences in September
|
English | 15.6 KB | ||
| 2025-08-07 12:30 |
Earnings Release
Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corpor…
|
English | 23.5 KB | ||
| 2025-06-24 12:30 |
Regulatory News Service
Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 …
|
English | 15.2 KB | ||
| 2025-06-05 12:30 |
Legal Proceedings Report
Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Re…
|
English | 18.3 KB | ||
| 2025-06-02 12:30 |
Regulatory News Service
Immunic to Participate in Investor, Scientific and Industry Conferences in June
|
English | 13.9 KB |
Automate Your Workflow. Get a real-time feed of all Immunic AG filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Immunic AG
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Immunic AG via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
